Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.

Nat Commun · 2026 · PMC13385651 · PMID 42185255

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

nominally significantno p-value reported

Results were stratified into significance tiers: highly significant (FDR < 0.05), nominally significant (FDR < 0.10), and exploratory (FDR < 0.25), given the nature of this biomarker discovery study.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.